Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

Geoffrey Coxon, Christopher B. Cooper, Stephen H. Gillespie, Timothy D. McHugh

Research output: Contribution to journalLiterature review

16 Citations (Scopus)

Abstract

There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.
LanguageEnglish
JournalJournal of Infectious Diseases
Early online date22 Mar 2012
DOIs
Publication statusE-pub ahead of print - 22 Mar 2012

Fingerprint

Drug Discovery
Tuberculosis
Pharmaceutical Preparations
Biosynthetic Pathways
Infection
Biological Products
Mycobacterium tuberculosis
Libraries
Pediatrics
Enzymes

Keywords

  • tuberculosis
  • drug discovery
  • antituberculosis

Cite this

@article{bd1f112cf40d4b67a09901f751ca0ad6,
title = "Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery",
abstract = "There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.",
keywords = "tuberculosis, drug discovery, antituberculosis",
author = "Geoffrey Coxon and Cooper, {Christopher B.} and Gillespie, {Stephen H.} and McHugh, {Timothy D.}",
year = "2012",
month = "3",
day = "22",
doi = "10.1093/infdis/jis191",
language = "English",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",

}

Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. / Coxon, Geoffrey; Cooper, Christopher B.; Gillespie, Stephen H.; McHugh, Timothy D.

In: Journal of Infectious Diseases, 22.03.2012.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

AU - Coxon, Geoffrey

AU - Cooper, Christopher B.

AU - Gillespie, Stephen H.

AU - McHugh, Timothy D.

PY - 2012/3/22

Y1 - 2012/3/22

N2 - There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.

AB - There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.

KW - tuberculosis

KW - drug discovery

KW - antituberculosis

UR - http://www.scopus.com/inward/record.url?scp=84860354911&partnerID=8YFLogxK

U2 - 10.1093/infdis/jis191

DO - 10.1093/infdis/jis191

M3 - Literature review

JO - Journal of Infectious Diseases

T2 - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -